Their study showed that U87 cells, a widely used glioblastoma cell line originally derived from a human GBM tumor, exhibited widespread transcriptional changes to the CB2R inverse agonist AM630, including suppression of cell cycle regulators and activation of immune‐related pathways such as TP53 and interferon signaling. This evidence concerns the gene TP53 and neoplasm.